134 related articles for article (PubMed ID: 24790008)
1. A retrospective study on the influence of nutritional status on pain management in cancer patients using the transdermal fentanyl patch.
Takahashi H; Chiba T; Tairabune T; Kimura Y; Wakabayashi G; Takahashi K; Kudo K
Biol Pharm Bull; 2014; 37(5):853-7. PubMed ID: 24790008
[TBL] [Abstract][Full Text] [Related]
2. Efficacy, safety and pharmacokinetic study of a novel fentanyl-containing matrix transdermal patch system in Japanese patients with cancer pain.
Miyazaki T; Hanaoka K; Namiki A; Ogawa S; Kitajima T; Hosokawa T; Ishida T; Nogami S; Mashimo S
Clin Drug Investig; 2008; 28(5):313-25. PubMed ID: 18407717
[TBL] [Abstract][Full Text] [Related]
3. [Three-day-type transdermal fentanyl patch conversion by rapid titration method with short-acting oral oxycodone for cancer pain].
Yamazaki K; Fujio N; Ishikawa N; Watanabe H; Kameyama M
Gan To Kagaku Ryoho; 2012 Mar; 39(3):405-8. PubMed ID: 22421768
[TBL] [Abstract][Full Text] [Related]
4. Controlled-release oxycodone tablets after transdermal-based opioid therapy in patients with cancer and non-cancer pain.
Ravera E; Di Santo S; Bosco R; Arboscello C; Chiarlone R
Aging Clin Exp Res; 2011; 23(5-6):328-32. PubMed ID: 22526067
[TBL] [Abstract][Full Text] [Related]
5. Cancer Cachexia May Hinder Pain Control When Using Fentanyl Patch.
Chiba T; Takahashi H; Tairabune T; Kimura S; Ueda H; Kudo K
Biol Pharm Bull; 2020; 43(5):873-878. PubMed ID: 32378563
[TBL] [Abstract][Full Text] [Related]
6. A new once-a-day fentanyl citrate patch (Fentos Tape) could be a new treatment option in patients with end-of-dose failure using a 72-h transdermal fentanyl matrix patch.
Koike K; Terui T; Nagasako T; Horiuchi I; Machino T; Kusakabe T; Hirayama Y; Mihara H; Yamakage M; Kato J; Nishisato T; Ishitani K
Support Care Cancer; 2016 Mar; 24(3):1053-9. PubMed ID: 26248654
[TBL] [Abstract][Full Text] [Related]
7. Clinical experience with transdermal and orally administered opioids in palliative care patients--a retrospective study.
Clemens KE; Klaschik E
Jpn J Clin Oncol; 2007 Apr; 37(4):302-9. PubMed ID: 17519302
[TBL] [Abstract][Full Text] [Related]
8. Factors predicting requirement of high-dose transdermal fentanyl in opioid switching from oral morphine or oxycodone in patients with cancer pain.
Kanbayashi Y; Hosokawa T; Okamoto K; Fujimoto S; Konishi H; Otsuji E; Yoshikawa T; Takagi T; Miki T; Taniwaki M
Clin J Pain; 2011 Oct; 27(8):664-7. PubMed ID: 21471811
[TBL] [Abstract][Full Text] [Related]
9. A safe and effective method for converting patients from transdermal to intravenous fentanyl for the treatment of acute cancer-related pain.
Kornick CA; Santiago-Palma J; Schulman G; O'Brien PC; Weigand S; Payne R; Manfredi PL
Cancer; 2003 Jun; 97(12):3121-4. PubMed ID: 12784350
[TBL] [Abstract][Full Text] [Related]
10. Risk Factors for Poor Pain Control after Opioid Switching from Oxycodone Tablet to Fentanyl Patch.
Morikawa N; Kasahara Y; Takahashi Y; Nishikura K; Nishihara M
Biol Pharm Bull; 2019; 42(10):1674-1678. PubMed ID: 31582655
[TBL] [Abstract][Full Text] [Related]
11. Video Education Reduces Pain and Anxiety Levels in Cancer Patients Who First Use Fentanyl Transdermal Patch: A Randomized Controlled Trial.
Ye Z; Chen J; Zhang Y; Hu X; Xuan Z; Yang S; Mao X; Rao Y
Drug Des Devel Ther; 2020; 14():3477-3483. PubMed ID: 32921984
[TBL] [Abstract][Full Text] [Related]
12. A feasibility study of transdermal buprenorphine versus transdermal fentanyl in the long-term management of persistent non-cancer pain.
Mitra F; Chowdhury S; Shelley M; Williams G
Pain Med; 2013 Jan; 14(1):75-83. PubMed ID: 23320402
[TBL] [Abstract][Full Text] [Related]
13. The efficacy of low-dose transdermal fentanyl in opioid-naïve cancer patients with moderate-to-severe pain.
Kang JH; Oh SY; Song SY; Lee HY; Kim JH; Lee KE; Lee HR; Hwang IG; Park SH; Kim WS; Park YS; Park K
Korean J Intern Med; 2015 Jan; 30(1):88-95. PubMed ID: 25589840
[TBL] [Abstract][Full Text] [Related]
14. A randomized, open, parallel group, multicenter trial to investigate analgesic efficacy and safety of a new transdermal fentanyl patch compared to standard opioid treatment in cancer pain.
Kress HG; Von der Laage D; Hoerauf KH; Nolte T; Heiskanen T; Petersen R; Lundorff L; Sabatowski R; Krenn H; Rosland JH; Saedder EA; Jensen NH
J Pain Symptom Manage; 2008 Sep; 36(3):268-79. PubMed ID: 18538974
[TBL] [Abstract][Full Text] [Related]
15. Equipotent doses of transdermal fentanyl and transdermal buprenorphine in patients with cancer and noncancer pain: results of a retrospective cohort study.
Sittl R; Likar R; Nautrup BP
Clin Ther; 2005 Feb; 27(2):225-37. PubMed ID: 15811486
[TBL] [Abstract][Full Text] [Related]
16. Changes in the prescribed daily doses of transdermal fentanyl and transdermal buprenorphine during treatment of patients with cancer and noncancer pain in Germany: results of a retrospective cohort study.
Sittl R; Nuijten M; Nautrup BP
Clin Ther; 2005 Jul; 27(7):1022-31. PubMed ID: 16154481
[TBL] [Abstract][Full Text] [Related]
17. Initial dose cascade of TTS fentanyl with proper adjuvant medications in cancer pain.
Baik SW; Kim KH; Kim YC; Lee SC; Kim DK; Jung JE
J Korean Med Sci; 2003 Oct; 18(5):733-7. PubMed ID: 14555829
[TBL] [Abstract][Full Text] [Related]
18. Transdermal buprenorphine patches applied in a 4-day regimen versus a 3-day regimen: a single-site, Phase III, randomized, open-label, crossover comparison.
Likar R; Lorenz V; Korak-Leiter M; Kager I; Sittl R
Clin Ther; 2007 Aug; 29(8):1591-606. PubMed ID: 17919542
[TBL] [Abstract][Full Text] [Related]
19. Indication of Adequate Transdermal Fentanyl Dose in Opioid Switching From Oral Oxycodone in Patients With Cancer.
Matsumura C; Yamada M; Fujihara S; Chisaki Y; Takahashi K; Yano Y
Am J Hosp Palliat Care; 2016 Mar; 33(2):109-14. PubMed ID: 25324418
[TBL] [Abstract][Full Text] [Related]
20. Use of Fentanyl Patch for Treatment of Moderate-to-severe Chronic Noncancer Pain: Postmarketing Surveillance of Medical Practice in Japan Using a Risk Minimization Action Plan.
Kawai K; Yoshizawa K; Fujie M; Kobayashi H; Ogawa Y; Yajima T
Pain Pract; 2017 Feb; 17(2):239-248. PubMed ID: 27080988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
